Advanced search
Publication Cover
Leukemia & Lymphoma Volume 53, 2012 - Issue 5
Submit an article Journal homepage
296
Views
18
CrossRef citations to date
0
Altmetric
Letter

Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response

Massimo BrecciaDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, ItalyCorrespondence[email protected]
,
Giuseppina LoglisciDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
,
Laura CannellaDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
,
Paola FinsingerDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
,
Marco ManciniDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
,
Alessandra SerraoDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
,
Michelina SantopietroDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
,
Adriano SalaroliDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
&
Giuliana AlimenaDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
 show all
Pages 985-986 | Received 28 Oct 2011, Accepted 18 Nov 2011, Published online: 11 Jan 2012

References

  • Silverman LR, Demakos EP, Peterson BL, . Randomized, controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002;20:2429–2440.
  • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, . Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open label, phase III study. Lancet Oncol 2009;10:223–232.
  • Itzykson R, Thepot S, Quesnel B, . Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011;117:403–411.
  • Vardiman JW, Thiele J, Arber DA, . The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114: 937–951.
  • Cheson BD, Greenberg PL, Bennett JM, . Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419–425.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.